- Avicanna has launched RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada
- The Toronto-based biopharmaceutical company explained that RHO Phyto Micro Drop 100 is designed to deliver enhanced absorption of cannabinoids through an inverted emulsion technology
- RHO Phyto Micro Drop 100 will only be available to patients with medical authorization at MyMedi.ca
- Shares of Avicanna last traded at $0.51
Avicanna (TSX:AVCN) has launched RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.
In a news release, the Toronto-based biopharmaceutical company explained that RHO Phyto Micro Drop 100 is designed to deliver enhanced absorption of cannabinoids through an inverted emulsion technology.
RHO Phyto Micro Drop 100 contains the same proprietary oral formulation as Trunerox, which received drug approval in Colombia last month to treat for severe seizures related to Lennox-Gastaut Syndrome and Dravet Syndrome. Trunerox has not been approved by Health Canada.
More details on this, and other products from the company, will likely be divulged May 13 when the company takes the stage as host of its 4th Medical Symposium on cannabinoid-based medicine in the Canadian Healthcare System for health care practitioners, scientists, researchers and the medical community.
RHO Phyto Micro Drop 100 will only be available to patients with medical authorization at MyMedi.ca.
Avicanna is an international biopharmaceutical company focused on developing and commercializing evidence-based cannabinoid products for the medical and pharmaceutical market segments.
Shares of Avicanna (TSX:AVCN) lost more than 3 per cent and finished at $0.51. Its stock is trading 39.47 per cent higher than this time last year.
Join the discussion: Find out what everybody’s saying about this stock on the Avicanna Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
